Michael Wasserman

Michael focuses on investments in therapeutics and medical devices and currently serves as a director or board observer for H.I.G. portfolio companies: HyperBranch Medical Technology, Clarus Therapeutics, Tranzyme Pharma, and CardioFocus.

Prior to joining H.I.G., Michael was a Principal at Innovations Foundation, focused on the creation, financing and development of high technology companies in the life sciences, information technology and engineering sectors.

At Innovations Foundation, Michael was instrumental in building multiple high growth companies derived from academic or federally sponsored research programs.

Michael has also held prominent operating roles in several entrepreneurial and venture-backed life sciences efforts.

Michael was a founder and Vice President, Business Development at CELLutions Biosystems (acquired by Cedarlane Laboratories), where he broadly managed business operations and was directly responsible for the successful negotiation of partnership, co-development and licensing agreements with industry leading pharmaceutical and biotechnology organizations.

Michael also has extensive clinical research experience.

As Director of Research at Advanced Therapeutics, Michael was involved in a series of seminal clinical studies involving biological approaches to treat rheumatoid arthritis and other autoimmune and inflammatory disorders.

Earlier in his career, Michael worked directly for, or as a consultant to, several early stage life sciences businesses, and in the corporate finance, pharmaceutical and clinical research industries.

Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology from the University of Toronto.

Michael Wasserman is the Bord of Directors at Clarus Therapeutics, based in North America. With a background in Biotechnology, Michael Wasserman has a rich history of leadership and innovation. Michael Wasserman studied unknown unknown @ McGill University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.